These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 26314551)

  • 21. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of KIAA1549::BRAF fusions and clinicopathological insights of pilocytic astrocytomas.
    Dandapath I; Das S; Charan BD; Garg A; Suri A; Kedia S; Sharma MC; Sarkar C; Khonglah Y; Ahmed S; Suri V
    Ann Diagn Pathol; 2024 Oct; 72():152318. PubMed ID: 38733671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
    Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
    PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse
    Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
    Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
    Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
    J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
    Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
    JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms.
    Wang L; Basturk O; Wang J; Benayed R; Middha S; Zehir A; Linkov I; Rao M; Aryeequaye R; Cao L; Chmielecki J; Ross J; Stephens PJ; Adsay V; Askan G; Balci S; Klimstra DS
    Mod Pathol; 2018 Jan; 31(1):132-140. PubMed ID: 28884748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.
    Kurani H; Gurav M; Shetty O; Chinnaswamy G; Moiyadi A; Gupta T; Jalali R; Epari S
    Childs Nerv Syst; 2019 Sep; 35(9):1525-1536. PubMed ID: 31321520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.
    Becker AP; Scapulatempo-Neto C; Carloni AC; Paulino A; Sheren J; Aisner DL; Musselwhite E; Clara C; Machado HR; Oliveira RS; Neder L; Varella-Garcia M; Reis RM
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):743-54. PubMed ID: 26083571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Turner JA; Bemis JGT; Bagby SM; Capasso A; Yacob BW; Chimed TS; Van Gulick R; Lee H; Tobin R; Tentler JJ; Pitts T; McCarter M; Robinson WA; Couts KL
    Oncogene; 2019 Feb; 38(8):1296-1308. PubMed ID: 30254212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum.
    Faulkner C; Ellis HP; Shaw A; Penman C; Palmer A; Wragg C; Greenslade M; Haynes HR; Williams H; Lowis S; White P; Williams M; Capper D; Kurian KM
    J Neuropathol Exp Neurol; 2015 Sep; 74(9):867-72. PubMed ID: 26222501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
    Seghers AC; Wilgenhof S; Lebbé C; Neyns B
    Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
    Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
    Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.